vapetrinity.com — FDA Warning Letter, 2026-05-19: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
TL;DR
Here's the summary: FDA issued a Warning Letter to vapetrinity.com on 2026-05-19 citing: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vapetrinitycom-730109-05192026
Argus analysis
vapetrinity.com (MARCS-CMS 730109) received an FDA Warning Letter dated May 19, 2026 from the Center for Tobacco Products. The letter cites: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on May 20, 2026.
ENDS/vapor letters cite the Family Smoking Prevention and Tobacco Control Act, primarily section 910's premarket review requirement for new tobacco products. FDA has run recurring enforcement sweeps against online retailers selling flavored, unauthorized e-liquid and disposable-vape SKUs that never cleared a Premarket Tobacco Product Application (PMTA).
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same tobacco/ENDS category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Tobacco letters cite the Family Smoking Prevention and Tobacco Control Act, primarily Section 910 (premarket review of new tobacco products) for ENDS / e-vapor SKUs.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER vapetrinity.com MARCS-CMS 730109 — May 19, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Reference #: RW2602413 Product: Tobacco Recipient: vapetrinity.com United States muninrym2@outlook.com Issuing Office: Center for Tobacco Products United States May 19, 2026 WARNING LETTER To Whom It May Concern: The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https://www.vapetrinity.com and determined that a dissolvable tobacco product listed there is offered for sale or distribution to customers in the United States. Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), this product is a tobacco product because it is made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including dissolvable tobacco products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1 and are required to be in compliance with the requirements in the FD&C Act. Generally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)). New Tobacco Product Without Required Marketing Authorization is Adulterated and Misbranded FDA has determined that you offer for sale or distribution to customers in the United States a dissolvable tobacco product that lacks a marketing authorization order: Lost Mary Airplane Mode Strawberry Nicotine Film – 2mg/Strip – 20pk. The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adultera…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to vapetrinity.com publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vapetrinitycom-730109-05192026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Tobacco / ENDS warning letter?
- Tobacco letters cite the Family Smoking Prevention and Tobacco Control Act, primarily Section 910 (premarket review of new tobacco products) for ENDS / e-vapor SKUs.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). vapetrinity.com — FDA Warning Letter, 2026-05-19: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-vapetrinity-com-2026-05-19-tobacco
"vapetrinity.com — FDA Warning Letter, 2026-05-19: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-vapetrinity-com-2026-05-19-tobacco.
Argus HQ Research. "vapetrinity.com — FDA Warning Letter, 2026-05-19: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-vapetrinity-com-2026-05-19-tobacco.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_vapetrinity_com_2026_05_19_tobacco_2026,
title = {vapetrinity.com — FDA Warning Letter, 2026-05-19: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-vapetrinity-com-2026-05-19-tobacco},
note = {Accessed: July 13, 2026}
}